Biotechnology

Kymera Therapeutics' new lupus data isn't just about a drug. It's about a new strategy: erasing disease-causing proteins to build resilient value.

Phenomenex, a Danaher company, launches its Luna Omega HILIC columns, aiming to simplify complex analysis in pharma, food safety, and diagnostics.

With a new CMO known for getting drugs approved, Protego Biopharma is betting big on its novel approach to treating a devastating rare disease.

Amai Proteins' sweelin® just got a major scientific boost. New clinical data in a top journal proves its metabolic safety, fast-tracking its commercial journey.

With its new SmartBioSurface slides, Italian firm Tethis aims to solve a major lab challenge. The key? A nanotech surface that could reshape disease research.

Hong Kong's NatureU touts impressive anti-aging results on a public registry, but a closer look reveals a complex strategy blending early science with savvy marketing.

Zealand Pharma's petrelintide shows double-digit weight loss with remarkably few side effects, positioning it to challenge GLP-1 giants in the $100B market.

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?

A small biotech is about to reveal data on a novel drug that could change autoimmune care. Will its bold scientific strategy pay off for patients and investors?

As Pacira BioSciences fends off an activist investor, a high-stakes proxy fight pits long-term R&D against demands for short-term returns.

A small biotech just unveiled data for an oral weight-loss pill that appears twice as effective as a key competitor in early tests, shaking up the market.

A breakthrough biomarker, DNlite™, analyzes landmark trial data, offering a new way to identify high-risk diabetes patients missed by current standards.

With its new SYNMUE™ probiotic, SynbioTech is targeting the biological clock of our immune system. A deep dive into the science, the strategy, and the execution.

With the approval of its advanced cancer drug Eratrectinib, Vcare PharmaTech challenges global rivals, showcasing China's AI-driven R&D and strategic ambition.

Market research shows doctors are eager to prescribe Moleculin's new AML drug, Annamycin. It offers hope where there is none, but can the company survive to deliver it?

BioCardia’s innovative cell therapy for heart failure receives a crucial FDA signal, potentially paving the way for a new treatment paradigm for millions.

A new drug promises the brain-rewiring benefits of psychedelics without the trip. Can Clearmind Medicine's CMND-100 transform addiction treatment?

Sanofi deepens its partnership with Owkin, licensing its 'K Pro' platform to build autonomous AI agents. A look at the strategy behind this major bet.

Landmark trial results for Bayer's KERENDIA unlock a vast new market in non-diabetic kidney disease, offering hope to millions and a strategic win for the firm.

Struggling biotech Tempest Therapeutics adds finance and medical heavyweights to its board. Is this a strategic reset or a last-ditch effort to survive?